AccueilGLTO • NASDAQ
add
Galecto Inc
Dernière clôture
5,14 $
Variation sur la journée
4,99 $ - 5,31 $
Plage sur l'année
4,40 $ - 23,50 $
Capitalisation boursière
6,70 M USD
Volume moyen
19,06 k
Ratio cours/bénéfices
-
Rendement (dividendes)
-
Place boursière principale
NASDAQ
Actualités
Données financières
Compte de résultat
Chiffre d'affaires
Résultat net
| (USD) | sept. 2024info | Variation Y/Y |
|---|---|---|
Chiffre d'affaires | — | — |
Charges d'exploitation | 3,84 M | -34,42 % |
Résultat net | -3,88 M | 52,27 % |
Marge bénéficiaire nette | — | — |
Bénéfice par action | -3,39 | 32,03 % |
EBITDA | -3,83 M | 32,07 % |
Taux d'imposition effectif | -0,18 % | — |
Bilan
Total des actifs
Total du passif
| (USD) | sept. 2024info | Variation Y/Y |
|---|---|---|
Trésorerie/Invest. court terme | 19,68 M | -55,46 % |
Total des actifs | 23,38 M | -53,29 % |
Total du passif | 2,44 M | -80,73 % |
Total des capitaux propres | 20,94 M | — |
Actions en circulation | 1,32 M | — |
Ratio cours/valeur comptable | 0,31 | — |
Rentabilité des actifs | -37,89 % | — |
Retour sur capitaux | -43,02 % | — |
Flux de trésorerie
Variation nette en trésorerie
| (USD) | sept. 2024info | Variation Y/Y |
|---|---|---|
Résultat net | -3,88 M | 52,27 % |
Trésorerie (opérations) | -3,65 M | 56,81 % |
Trésorerie (invest.) | 0,00 | -100,00 % |
Trésorerie (financement) | — | — |
Variation nette en trésorerie | -3,18 M | -2 709,84 % |
Flux de trésorerie dispo. | -2,08 M | 44,50 % |
À propos
Galecto Biotech is a biotechnology company that develops small molecules for the treatment of severe diseases, including fibrosis, cancer and inflammation. The company was founded in 2011 by leading galectin scientists and biotech executives from Sweden, United Kingdom, and Denmark. The company today is incorporated in the U.S., and has its operating headquarters in Copenhagen, Denmark.
The company builds on more than 10 years of research centering on the role of galectin-3 and LOXL-2, and the use of modulators of these proteins to treat fibrosis-related diseases and cancer. Combined with a strong patent estate, these assets give Galecto a unique therapeutic platform.
Galecto's lead product candidate, GB0139, is an inhaled inhibitor of galectin-3. GB0139 is being developed for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, in which there is high unmet medical need. Wikipedia
Date de fondation
2011
Siège social
Site Web
Employés
13
